- Home
- BCHT vs TCRX Comparison
BCHT vs TCRX Comparison
Compare BCHT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCHT | TCRX |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.2M | 49.4M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCHT | TCRX |
|---|---|---|
| Price | $1.40 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $15.00 | $7.00 |
| AVG Volume (30 Days) | 63.8K | ★ 774.1K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $61.22 | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $1.26 | $0.73 |
| 52 Week High | $2.48 | $2.57 |
Technical Indicators
Market Signals| Indicator | BCHT | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 33.47 |
| Support Level | $1.26 | N/A |
| Resistance Level | $1.58 | $1.16 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 9.44 | 2.40 |
Price Performance
Historical ComparisonAbout BCHT Birchtech Corp. Common Stock
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.